Development and optimization of levodopa and benzylhydrazine orally disintegrating tablets by direct compression and response surface methodology

References

• Bette S, Shpiner DS, Singer C, et al. Safinamide in the management of patients with Parkinson’s disease not stabilized on levodopa: a review of the current clinical evidence. Ther Clin Risk Manag. 2018;14:1737.
   PubMed Web of Science ®Google Scholar
• Loens S, Chorbadzhieva E, Kleimann A, et al. Effects of levodopa/carbidopa intestinal gel versus oral levodopa/carbidopa on B vitamin levels and neuropathy. Brain Behav. 2017;7(5):e00698.
   PubMed Web of Science ®Google Scholar
• Nyholm D, Lewander T, Gomes-Trolin C, et al. Pharmacokinetics of levodopa/carbidopa microtablets versus levodopa/benserazide and levodopa/carbidopa in healthy volunteers. Clin Neuropharmacol. 2012;35(3):111–117.
   PubMed Web of Science ®Google Scholar
• Lipp MM, Batycky R, Moore J, et al. Preclinical and clinical assessment of inhaled levodopa for OFF episodes in Parkinson’s disease. Sci Transl Med. 2016;8(360):360ra136.
   PubMed Web of Science ®Google Scholar
• Zulli C, Sica M, De RM, et al. Continuous intra jejunal infusion of levodopa-carbidopa intestinal gel by jejunal extension tube placement through percutaneous endoscopic gastrostomy for patients with advanced Parkinson’s disease: a preliminary study. Eur Rev Med Pharmacol Sci. 2016;20(11):2413–2417.
   PubMed Web of Science ®Google Scholar
• Müller T, Möhr J-D. Efficacy of carbidopa-levodopa extended-release capsules (IPX066) in the treatment of Parkinson Disease. Expert Opin Pharmacother. 2018;19(18):2063–2071.
   PubMed Web of Science ®Google Scholar
• Hauser RA, Isaacson SH, Ellenbogen A, et al. Orally inhaled levodopa (CVT-301) for early morning OFF periods in Parkinson’s disease. Parkinsonism Relat Disord. 2019;64:175–180.
   PubMed Web of Science ®Google Scholar
• Borges AF, Silva C, Coelho JFJ, et al. Outlining critical quality attributes (CQAs) as guidance for the development of orodispersible films. Pharm Dev Technol. 2017;22(2):237–245.
   PubMed Web of Science ®Google Scholar
• Chen Y, Feng T, Li Y, et al. Formulation and evaluation of a montelukast sodium orally disintegrating tablet with a similar dissolution profile as the marketed product. Pharm Dev Technol. 2017;22(2):168–172.
   PubMed Web of Science ®Google Scholar
• Hirani JJ, Rathod DA, Vadalia KR. Orally disintegrating tablets: a review. Trop. J. Pharm. Res. 2009;8(2):161–172.
   Web of Science ®Google Scholar
• Kakutani R, Muro H, Makino T. Development of a new disintegration method for orally disintegrating tablets. Chem Pharm Bull. 2010;58(7):885–890.
   PubMed Web of Science ®Google Scholar
• Olmez SS, Vural I. Advantages and quality control of orally disintegrating tablets. FABAD J Pharm Sci. 2009;34:167–172.
   Google Scholar
• Stange U, Führling C, Gieseler H. Freeze drying of orally disintegrating tablets containing taste masked naproxen sodium granules in blisters. Pharm Dev Technol. 2015;20(8):1018–1024.
   PubMed Web of Science ®Google Scholar
• Nausieda PA, Pfeiffer RF, Tagliati M, et al. A multicenter, open-label, sequential study comparingpreferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson’s disease. Clin Ther. 2005;27(1):58–63.
   PubMed Web of Science ®Google Scholar
• Ondo WG, Shinawi L, Moore S. Comparison of orally dissolving carbidopa/levodopa (Parcopa) to conventional oral carbidopa/levodopa: a single-dose, double-blind, double-dummy, placebo-controlled, crossover trial. Mov Disord. 2010;25(16):2724–2727.
   PubMed Web of Science ®Google Scholar
• Goel H, Rai P, Rana V, et al. Orally disintegrating systems: innovations in formulation and technology. Recent Pat Drug Deliv Formul. 2008;2(3):258–274.
   PubMedGoogle Scholar
• Bi YX, Sunada H, Yonezawa Y, et al. Evaluation of rapidly disintegrating tablets prepared by a direct compression method. Drug Dev Ind Pharm. 1999;25(5):571–581.
   PubMed Web of Science ®Google Scholar
• Gulsun T, Cayli YA, Izat N, et al. Development and evaluation of terbutaline sulfate orally disintegrating tablets by direct compression and freeze drying methods. J Drug Deliv Sci Technol. 2018;46:251–258.
   Web of Science ®Google Scholar
• Amiri S, Shakeri A, Sohrabi MR, et al. Optimization of ultrasonic assisted extraction of fatty acids from Aesculus hippocastanum fruit by response surface methodology. Food Chem. 2019;271:762–766.
   PubMed Web of Science ®Google Scholar
• Ibrahim MA, El Sayeh FA. Optimized furosemide taste masked orally disintegrating tablets. Saudi Pharm J. 2017;25(7):1055–1062.
   PubMed Web of Science ®Google Scholar
• Liu Y, Li P, Qian R, et al. A novel and discriminative method of in vitro disintegration time for preparation and optimization of taste-masked orally disintegrating tablets of carbinoxamine maleate. Drug Dev Ind Pharm. 2018;44(8):1317–1327.
   PubMed Web of Science ®Google Scholar
• Macías-Sánchez MD, Robles-Medina A, Jiménez-Callejón MJ, et al. Optimization of biodiesel production from wet microalgal biomass by direct transesterification using the surface response methodology. Renew Energy. 2018;129:141–149.
   Web of Science ®Google Scholar
• National Pharmacopoeia Committee. Pharmacopoeia of the People’s Republic of China, Part 4. Beijing, China: Pharmaceutical press; 2015. p. 162–179.
   Google Scholar
• Yehia SA, El-Ridi MS, Tadros MI, et al. Phenylalanine-free taste-masked orodispersible tablets of fexofenadine hydrochloride: development, in vitro evaluation and in vivo estimation of the drug pharmacokinetics in healthy human volunteers. Pharm Dev Technol. 2015;20(5):528–539.
   PubMed Web of Science ®Google Scholar
• Yoshita T, Uchida S, Namiki N. Clinical disintegration time of orally disintegrating tablets clinically available in Japan in healthy volunteers. Biol Pharm Bull. 2013;36:1488–1493.
   PubMed Web of Science ®Google Scholar
• Sotoyama M, Uchida S, Tanaka S, et al. Citric acid suppresses the bitter taste of olopatadine hydrochloride orally disintegrating tablets. Biol Pharm Bull. 2017;40(4):451–457.
   PubMed Web of Science ®Google Scholar
• Malladi M, Jukanti R, Nair R, et al. Design and evaluation of taste masked dextromethorphan hydrobromide oral disintegrating tablets. Acta Pharm. 2010;60(3):267–280.
   PubMed Web of Science ®Google Scholar
• Usmani MT, Shoaib MH, Nasiri MI, et al. Development and evaluation of orally disintegrating tablets of Montelukast sodium by direct compression method. Trop J Pharm Res. 2015;14(1):1–6.
   Web of Science ®Google Scholar
• Wu T, Wang G, Shi C, et al. Development and evaluation of orally disintegrating tablet containing mosapride resin complex. Acta Pharm. 2018;68(2):159–170.
   PubMed Web of Science ®Google Scholar
• Abdelbary G, Eouani C, Prinderre P, et al. Determination of the in vitro disintegration profile of rapidly disintegrating tablets and correlation with oral disintegration. Int J Pharm. 2005;292(1-2):29–41.
   PubMedGoogle Scholar
• Battu SK, Repka MA, Majumdar S, et al. Formulation and evaluation of rapidly disintegrating fenoverine tablets: effect of superdisintegrants. Drug Dev Ind Pharm. 2007;33(11):1225–1232.
   PubMed Web of Science ®Google Scholar
• Ibrahim AH, Rosqvist E, Smått J-H, et al. Formulation and optimization of lyophilized nanosuspension tablets to improve the physicochemical properties and provide immediate release of silymarin. Int J Pharm. 2019;563:217–227.
   PubMedGoogle Scholar
• Gryczke A, Schminke S, Maniruzzaman M, et al. Development and evaluation of orally disintegrating tablets (ODTs) containing Ibuprofen granules prepared by hot melt extrusion. Colloids Surfaces B Biointerfaces. 2011;86(2):275–284.
   PubMed Web of Science ®Google Scholar
• Desai C, Prabhakar B. Development and evaluation of orally disintegrating tablets of cilostazol-β-cyclodextrin inclusion complexes. Drug Dev Ind Pharm. 2015;41(10):1589–1607.
   PubMed Web of Science ®Google Scholar
• Stoltenberg I, Breitkreutz J. Orally disintegrating mini-tablets (ODMTs)–a novel solid oral dosage form for paediatric use. Eur J Pharm Biopharm. 2011;78(3):462–469.
   PubMed Web of Science ®Google Scholar
• Takano H, Uchida S, Kashiwagura Y, et al. Preparation of cocoa powder-containing orally disintegrating tablets of rebamipide (Rebamipide Chocolet) and evaluation of their clinical palatability. Chem Pharm Bull. 2019;67(2):112–119.
   PubMed Web of Science ®Google Scholar
• Nakamura H, Uchida S, Sugiura T, et al. The prediction of the palatability of orally disintegrating tablets by an electronic gustatory system. Int J Pharm. 2015;493(1-2):305–312.
   PubMedGoogle Scholar
• Yıldız S, Aytekin E, Yavuz B, et al. Development and evaluation of orally disintegrating tablets comprising taste-masked mirtazapine granules. Pharm Dev Technol. 2018;23(5):488–495.
   PubMed Web of Science ®Google Scholar
• Mohite BP, Chafle SA, Somasundaram J, et al. Development and evaluation of ofloxacin orally disintegrating tablets. Braz J Pharm Sci. 2012;48(2):217–225.
   Web of Science ®Google Scholar